The long third complementarity-determining region of the heavy chain is important in the activity of the broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2F5

被引:99
|
作者
Zwick, MB
Komori, HK
Stanfield, RL
Church, S
Wang, M
Parren, PWHI
Kunert, R
Katinger, H
Wilson, IA
Burton, DR
机构
[1] Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA
[2] Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA
[3] Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA
[4] Univ Nat Resources, Inst Appl Microbiol, Vienna, Austria
关键词
D O I
10.1128/JVI.78.6.3155-3161.2004
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The human monoclonal antibody 2F5 neutralizes primary human immunodeficiency virus type 1 (HfV-1) with rare breadth and potency. A crystal structure of a complex of 2F5 and a peptide corresponding to its core epitope on gp41, ELDKWAS, revealed that the peptide interacts with residues at the base of the unusually long (22-residue) third complementarity-determining region of the heavy chain (CDR H3) but not the apex. Here, we perform alanine-scanning mutagenesis across CDR H3 and make additional substitutions of selected residues to map the paratope of Fab 2F5. Substitution of residues from the base of the H3 loop or from CDRs H1, H2, and L3, which are proximal to the peptide, significantly diminished the affinity of Fab 2F5 for gp41 and a short peptide containing the 2F5 core motif. However, nonconservative substitutions to a phenylalanine residue at the apex of the H3 loop also markedly decreased 2F5 binding to both gp41 and the peptide, suggesting that recognition of the core epitope is crucially dependent on features at the apex of the H3 loop. Furthermore, substitution at the apex of the H3 loop had an even more pronounced effect on the neutralizing activity of 2F5 against three sensitive HIV-1. These observations present a challenge to vaccine strategies based on peptide mimics of the linear epitope.
引用
收藏
页码:3155 / 3161
页数:7
相关论文
共 50 条
  • [41] Anti-human immunodeficiency virus type 1 activity of R-95288, a phosphodiester hexadeoxyribonucleotide modified by dibenzyloxybenzyl and hydroxyethyl residues at the 5'- and 3'-ends
    Agatsuma, T
    Furukawa, H
    Hotoda, H
    Koizumi, M
    Koga, R
    Kaneko, M
    ANTIVIRAL CHEMISTRY & CHEMOTHERAPY, 1997, 8 (05): : 429 - 438
  • [42] 2-Sulfonyl-4-chloroanilino moiety: A potent pharmacophore for the anti-human immunodeficiency virus type 1 activity of pyrrolyl aryl sulfones
    Artico, M
    Silvestri, R
    Massa, S
    Loi, AG
    Corrias, S
    Piras, G
    LaColla, P
    JOURNAL OF MEDICINAL CHEMISTRY, 1996, 39 (02) : 522 - 530
  • [43] β-Actin-binding Complementarity-determining Region 2 of Variable Heavy Chain from Monoclonal Antibody C7 Induces Apoptosis in Several Human Tumor Cells and Is Protective against Metastatic Melanoma
    Arruda, Denise C.
    Santos, Luana C. P.
    Melo, Filipe M.
    Pereira, Felipe V.
    Figueiredo, Carlos R.
    Matsuo, Alisson L.
    Mortara, Renato A.
    Juliano, Maria A.
    Rodrigues, Elaine G.
    Dobroff, Andrey S.
    Polonelli, Luciano
    Travassos, Luiz R.
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2012, 287 (18) : 14912 - 14922
  • [44] The role of antibody polyspecificity and lipid reactivity in binding of broadly neutralizing anti-HIV-1 envelope human monoclonal antibodies 2F5 and 4E10 to glycoprotein 41 membrane proximal envelope epitopes
    Alam, S. Munir
    McAdams, Mildred
    Boren, David
    Rak, Michael
    Scearce, Richard M.
    Gao, Feng
    Camacho, Zenaido T.
    Gewirth, Daniel
    Kelsoe, Garnett
    Chen, Pojen
    Haynes, Barton F.
    JOURNAL OF IMMUNOLOGY, 2007, 178 (07): : 4424 - 4435
  • [45] PLASMA PHARMACOKINETICS AND BIOLOGICAL-ACTIVITY OF A HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 NEUTRALIZING HUMAN MONOCLONAL-ANTIBODY, F105, IN CYNOMOLGUS MONKEYS
    CAVACINI, LA
    POWER, J
    EMES, CL
    MACE, K
    TREACY, G
    POSNER, MR
    JOURNAL OF IMMUNOTHERAPY, 1994, 15 (04) : 251 - 256
  • [46] DESIGN, INTRACELLULAR EXPRESSION, AND ACTIVITY OF A HUMAN ANTI-HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 GP120 SINGLE-CHAIN ANTIBODY
    MARASCO, WA
    HASELTINE, WA
    CHEN, SY
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (16) : 7889 - 7893
  • [47] Wild type and H43Y variant of human TRIM5α show similar anti-human immunodeficiency virus type 1 activity both in vivo and in vitro
    Emi E. Nakayama
    Wassila Carpentier
    Dominique Costagliola
    Tatsuo Shioda
    Aikichi Iwamoto
    Patrice Debre
    Kazuhisa Yoshimura
    Brigitte Autran
    Shuzo Matsushita
    Ioannis Theodorou
    Immunogenetics, 2007, 59 : 511 - 515
  • [48] Wild type and H43Y variant of human TRIM5α show similar anti-human immunodeficiency virus type 1 activity both in vivo and in vitro
    Nakayama, Emi E.
    Carpentier, Wassila
    Costagliola, Dominique
    Shioda, Tatsuo
    Iwamoto, Aikichi
    Debre, Patrice
    Yoshimura, Kazuhisa
    Autran, Brigitte
    Matsushita, Shuzo
    Theodorou, Ioannis
    IMMUNOGENETICS, 2007, 59 (06) : 511 - 515
  • [49] Binding of the 2F5 monoclonal antibody to native and fusion-intermediate forms of human immunodeficiency virus type 1 gp41: Implications for fusion-inducing conformational changes
    de Rosny, E
    Vassell, R
    Jiang, S
    Kunert, R
    Weiss, CD
    JOURNAL OF VIROLOGY, 2004, 78 (05) : 2627 - 2631
  • [50] Impact of a single amino acid in the variable region 2 of the Old World monkey TRIM5α SPRY (B30.2) domain on anti-human immunodeficiency virus type 2 activity
    Kono, Ken
    Bozek, Katarzyna
    Domingues, Francisco S.
    Shioda, Tatsuo
    Nakayama, Emi E.
    VIROLOGY, 2009, 388 (01) : 160 - 168